-+ 0.00%
-+ 0.00%
-+ 0.00%

Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46

Benzinga·09/18/2026 11:40:13
Listen to the news
Deutsche Bank analyst David Hoang downgrades Xenon Pharmaceuticals (NASDAQ:XENE) from Buy to Hold and lowers the price target from $90 to $46.